Poster: MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) After In-Class Transition (iCT) From Parenteral Bortezomib-Based Induction Therapy to ALL-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd): Data From the Phase 4, Community-Based US Poster: MM-6 Study (Fully Accrued Cohort)

Subjects

Subjects :

Cancer Research
Oncology
Hematology

Details

ISSN :

21522650

Volume :

22

Database :

OpenAIRE

Journal :

Clinical Lymphoma Myeloma and Leukemia

Accession number :

edsair.doi...........a8b2f0ed22e825329d02556454dbc837

Full Text :

https://doi.org/10.1016/s2152-2650(22)01101-6